Corvus Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Corvus Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Corvus Pharmaceuticals Inc recorded a cumulative net loss of $-54 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -33.23%.

However, within the Healthcare sector 445 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3742, from total ROA ranking in the first quarter of 2026 at 4074.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	172.47 %	331.23 %	5.52 %	37.81 %	38.5 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-54	-44	-15	-15	-45
Return On Assets (TTM)	-33.23 %	-35.58 %	-20.24 %	-20.21 %	-65.43 %
CRVS's Total Ranking	# 3742	# 4074	# 3552	# 4243	# 4324
Total Assets (TTM) in million	245	253	72	82	90
Seq. Total Assets Change	-3.34 %	252.36 %	-12.04 %	-9.05 %	52.98 %
Seq. Net Income Change	-	-	-	-	-

CRVS's 5 Years Annual ROA >> Back to CRVS Management Effectiveness >> Compare CRVS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 172
Sector	# 446
Overall	# 3665

Return On Assets Statistics
High	Average	Low
-5.9 %	-43.65 %	-108.76 %
(Mar 31 2021)		(Sep 30 2024)

Financial Statements
Corvus Pharmaceuticals Inc 's Assets	$ 245 million	CRVS's Balance sheet
Corvus Pharmaceuticals Inc 's Income	$ -18 million	Quarterly CRVS's Income Statement
CRVS's Income by Division		See CRVS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	20.58 %	50.28 %	-32.26 %	-20.8 %	2.01 %
Total Assets in million	82	68	45	67	84
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-15	-62	-27	-41	-6
Annual Return On Assets	-18.61 %	-91.48 %	-59.65 %	-61.75 %	-7.1 %

CRVS's 5 Years Annual ROA >> Back to CRVS Management Effectiveness >> Compare CRVS ROA to its Competitors

More Return On Assets Ratios
CRVS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CRVS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CRVS's Competitors
Subscribers only: Roa for Corvus Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for CRVS's Customers

You may also want to know
CRVS's Roi	CRVS's Inventory Turnover Ratio	CRVS's Growth Rates	CRVS's Dividend Comparisons
	CRVS's Profitability Ratios	CRVS's Asset Turnover Ratio	CRVS's Dividend Growth
CRVS's Roe	CRVS's Valuation Ratios	CRVS's Financial Strength Ratios	CRVS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T13:43:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.